𝛼SK or Searchbullish
Racura Oncology (ASX:RAC): One drug, three shots
SUMMARY
- Venn Brown sat down with Daniel Tillett, CEO of Racura Oncology, to discuss the three potential applications for RC220, their potential market size, the status of its clinical trials, funding, and what the market doesn’t understand.
- Old drug, new delivery: RC220 reformulates bisantrene, an effective cancer drug developed in the 1980s but constrained by poor solubility and crystallisation in the blood.
- Racura’s formulation is designed to enable safer, more practical administration while preserving the drug’s underlying properties.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Racura Oncology (ASX:RAC): One drug, three shots03 Aug 2026
x